Council of Scientific and Industrial Research (CSIR) has taken one more strong initiative towards the battle against Novel corona virus (COVID-19). CSIR is going to implement repurposing of existing drugs (Sepsivac) to fight against COVID-19, which might be effective to treat COVID-19.
The drug Sepsivac is a recently approved drug for marketing in India from Ahmedabad based Cadila Pharmaceuticals Limited. This drug is used to treat gram-negative sepsis patients and now is going to be used for re-purposing against COVID-19.
There might be few important questions in your mind related to this drug, trial and its effect against COVID-19. I have tried to answer a few questions.
What CSIR said?
Watch full interview here in hindi
Shekhar Mande, Director General, CSIR, said, “This is a moment of pride for all of us as, it is the only such drug in the global market which has been approved to treat Gram-negative sepsis. If it works against Covid-19, it will be a major breakthrough. But we should have patience, and wait, as clinical trials are yet to begin,”
How Sepsivac works?
According to the Cadila pharmaceuticals, “Sepsivac contains mycobacterium W, an immune-modulator which is a non-pathogenic mycobacterium. As a result of the immune-modulator effect, Sepsivac effectively saves more lives in sepsis. Randomized trials in sepsis patients showed 11 % absolute reduction and 55.5% relative reduction in mortality.”
Why CSIR selected Sepsivac?
The patient of gram-negative sepsis and critical COVID-19 shows similar reactions in the human body. In these disease human body shows altered immune response, which leads to the change in cytokine profile. This massive cytokine release attacks to the human cells including harmful and beneficial cells both. This is an immune modulator drug which helps to inhibit the cytokine release. Hence, it decreases the death of cells.
What is the design of clinical trial?
CSIR is initiating a randomized, blinded, two arms and active comparator-controlled clinical trial. This trial will evaluate the drug efficacy for reducing cell deaths (mortality rate) in severely ill Covid-19 patients.
What is the status of clinical trial?
CSIR submitted the application to the Drugs Controller General of India (DCGI). Now, DCGI has approved the trial and preparation of the list of the clinical site has been initiated. It includes hospitals, medical institutes and other clinical sites.
What is drug repurposing?
This is a strategy, which discovers the new uses of an existing investigational or approved drug for other than the indication it was used for. This is also known as drug repositioning or reprofiling.
Till date this article published, there are no drugs or vaccines available for the treatment of COVID-19.
Stop The Rumors, Spread The Awareness